241 related articles for article (PubMed ID: 35278641)
1. Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways.
Cui Z; Li D; Zhao J; Chen K
Free Radic Biol Med; 2022 Apr; 183():106-124. PubMed ID: 35278641
[TBL] [Abstract][Full Text] [Related]
2. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.
Li JM; Yang F; Li J; Yuan WQ; Wang H; Luo YQ
Med Sci Monit; 2020 Aug; 26():e925298. PubMed ID: 32764530
[TBL] [Abstract][Full Text] [Related]
3. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer.
Lou JS; Zhao LP; Huang ZH; Chen XY; Xu JT; Tai WC; Tsim KWK; Chen YT; Xie T
Phytomedicine; 2021 Jan; 80():153370. PubMed ID: 33113504
[TBL] [Abstract][Full Text] [Related]
4. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.
Yang X; Meng L; Zhong Y; Hu F; Wang L; Wang M
Aging (Albany NY); 2021 Jan; 13(2):2864-2884. PubMed ID: 33418541
[TBL] [Abstract][Full Text] [Related]
5. Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non‑small lung cancer cells by regulating the YAP pathway.
Jin D; Wu Y; Shao C; Gao Y; Wang D; Guo J
Oncol Rep; 2018 Aug; 40(2):609-620. PubMed ID: 29901163
[TBL] [Abstract][Full Text] [Related]
6. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
7. Isovitexin potentiated the antitumor activity of cisplatin by inhibiting the glucose metabolism of lung cancer cells and reduced cisplatin-induced immunotoxicity in mice.
Chen RL; Wang Z; Huang P; Sun CH; Yu WY; Zhang HH; Yu CH; He JQ
Int Immunopharmacol; 2021 May; 94():107357. PubMed ID: 33715980
[TBL] [Abstract][Full Text] [Related]
8. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
9. NSC-87877 inhibits DUSP26 function in neuroblastoma resulting in p53-mediated apoptosis.
Shi Y; Ma IT; Patel RH; Shang X; Chen Z; Zhao Y; Cheng J; Fan Y; Rojas Y; Barbieri E; Chen Z; Yu Y; Jin J; Kim ES; Shohet JM; Vasudevan SA; Yang J
Cell Death Dis; 2015 Aug; 6(8):e1841. PubMed ID: 26247726
[TBL] [Abstract][Full Text] [Related]
10. Circ_0000079 Decoys the RNA-Binding Protein FXR1 to Interrupt Formation of the FXR1/PRCKI Complex and Decline Their Mediated Cell Invasion and Drug Resistance in NSCLC.
Chen C; Zhang M; Zhang Y
Cell Transplant; 2020; 29():963689720961070. PubMed ID: 32951448
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
12. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
13. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
14. Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer.
Chen Y; Zhou H; Yang S; Su D
Cell Biochem Funct; 2021 Mar; 39(2):277-286. PubMed ID: 32815556
[TBL] [Abstract][Full Text] [Related]
15. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-induced antizyme inhibitors 2 regulates cisplatin resistance through epithelia-mesenchymal transition pathway in non-small cell lung cancer.
Shi Q; Chen Q; Zhou Z; Zheng X; Huang X; Fang M; Hu Y; Song L; Yang H; Chen Q
Pulm Pharmacol Ther; 2021 Aug; 69():102048. PubMed ID: 34082109
[TBL] [Abstract][Full Text] [Related]
17. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
[TBL] [Abstract][Full Text] [Related]
18. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
[TBL] [Abstract][Full Text] [Related]
19. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
[TBL] [Abstract][Full Text] [Related]
20. USP3 promotes cisplatin resistance in non-small cell lung cancer cells by suppressing ACOT7-regulated ferroptosis.
Tao R; Liu Z; Zhang Z; Zhang Z
Anticancer Drugs; 2024 Jul; 35(6):483-491. PubMed ID: 38502867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
